Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPW5SB)

Drug Name
BAY 86-9766 Drug Info
Synonyms
923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333
Cross-matching ID
PubChem CID
44182295
ChEBI ID
CHEMBL1236682
CAS Number
CAS 923032-37-5
TTD Drug ID
D03SKL
INTEDE Drug ID
DR1879

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Lysosome 2.26 0.00e+0 115/128 (89.84%) CTSH;TPP1;PSAP;...
Other glycan degradation 1.98 7.11e-3 13/18 (72.22%) NEU1;HEXA;FUCA1;...
Oxidative phosphorylation 1.96 4.74e-3 93/133 (69.92%) ATP5MC2;ATP6V0E1;SDHA;...
Glycolysis / Gluconeogenesis 1.92 7.11e-3 56/67 (83.58%) ALDH3A2;GPI;ADH1B;...
Pentose phosphate pathway 1.87 1.71e-2 25/30 (83.33%) GPI;DERA;PFKP;...
Necroptosis 1.86 1.42e-2 113/159 (71.07%) TNFSF10;IRF9;PYCARD;...
Herpes simplex virus 1 infection 1.84 1.63e-2 165/498 (33.13%) BST2;IRF9;TAP1;...
Graft-versus-host disease 1.81 2.31e-2 32/42 (76.19%) HLA-F;HLA-B;HLA-C;...
Cardiac muscle contraction 1.78 2.53e-2 64/87 (73.56%) TNNC1;TPM1;ATP1B1;...
Metabolism of xenobiotics by cytochrome P450 1.77 2.56e-2 49/77 (63.64%) GSTM3;GSTK1;AKR1C1;...
Influenza A 1.77 2.46e-2 156/172 (90.7%) MX1;TNFSF10;IRF9;...
Allograft rejection 1.76 2.25e-2 32/38 (84.21%) HLA-F;HLA-B;HLA-C;...
Antigen processing and presentation 1.75 2.52e-2 60/78 (76.92%) TAP1;HLA-F;HLA-B;...
Axon guidance 1.75 2.64e-2 151/182 (82.97%) MYL9;EFNA1;ABLIM1;...
Histidine metabolism 1.69 4.84e-2 16/22 (72.73%) MAOA;ALDH3A2;ALDH2;...
IL-17 signaling pathway -1.57 4.52e-2 84/94 (89.36%) HSP90AA1;CCL20;CHUK;...
Purine metabolism -1.58 4.31e-2 102/129 (79.07%) DCK;PAPSS2;DGUOK;...
Base excision repair -1.61 3.37e-2 29/33 (87.88%) HMGB1;POLE;POLE3;...
Progesterone-mediated oocyte maturation -1.62 3.24e-2 75/100 (75%) CDC27;PRKACB;MAP2K1;...
Oocyte meiosis -1.63 3.05e-2 90/129 (69.77%) RPS6KA3;CALML5;PPP2R5E;...
Homologous recombination -1.65 2.21e-2 35/41 (85.37%) RPA1;MRE11;PALB2;...
mRNA surveillance pathway -1.81 4.88e-3 71/98 (72.45%) CPSF4;PAPOLA;CSTF2;...
One carbon pool by folate -1.81 5.32e-3 15/20 (75%) SHMT2;DHFR;GART;...
Cysteine and methionine metabolism -1.83 4.68e-3 43/50 (86%) GOT1;GOT2;APIP;...
Spliceosome -1.85 5.20e-3 101/150 (67.33%) DDX46;SNRPB2;SART1;...
Nucleotide excision repair -1.88 2.20e-3 40/47 (85.11%) ERCC1;POLE;RPA2;...
Pyrimidine metabolism -1.89 2.51e-3 40/56 (71.43%) NME7;ENTPD6;RRM1;...
Fanconi anemia pathway -1.92 1.95e-3 36/54 (66.67%) TELO2;ATR;RPA1;...
Mismatch repair -2.02 1.17e-3 22/23 (95.65%) RPA2;MLH1;RPA3;...
RNA transport -2.08 0.00e+0 128/186 (68.82%) EEF1A2;KPNB1;NUP210;...
Ribosome biogenesis in eukaryotes -2.14 0.00e+0 52/108 (48.15%) LSG1;NOL6;FBL;...
Cell cycle -2.37 0.00e+0 110/124 (88.71%) CDK2;ESPL1;PKMYT1;...
DNA replication -2.57 0.00e+0 34/36 (94.44%) POLA2;RNASEH1;RNASEH2A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H